Research Paper Volume 12, Issue 24 pp 25767—25777

Zinc oxide nanoparticles (ZnO NPs) combined with cisplatin and gemcitabine inhibits tumor activity of NSCLC cells

Figure 7. Anti-tumor activity of ZnO-NPs in vivo. (A) image of subcutaneous xenograft tumors.(B) Tumor weight. * P< 0.05 vs. Control.